Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1995-10-31
1998-05-05
Jarvis, William R.A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
A61K 31045
Patent
active
057475440
ABSTRACT:
A method is disclosed for treating or preventing macular degeneration, one of the leading causes of blindness and vision loss, by administering a preparation of zeaxanthin which contains the 3R-3'R stereoisomer as a sole or heavily dominant stereoisomer. Zeaxanthin, a yellowish pigment which is naturally present in macular cells in the center of the human retina, absorbs blue and near-ultraviolet light radiation, thereby protecting retinal cells against phototoxic damage. The purified R-R isomer of zeaxanthin can be taken orally as a prescription drug by patients suffering from macular degeneration, and it can also be used as a nutritional supplement, in forms such as a vitamin pills or food additives, by anyone who wants to reduce his or her risk of macular degeneration, which is widespread among people over the age of about 50 or 60. Zeaxanthin preparations which contain only the desired R-R isomer can be produced by fermentation of Flavobacterium multivorum cells (ATCC accession number 55238) or other host cells which contain genes isolated from this F. multivorum strain. These bacterial cells do not create any detectable quantities of the undesired S-S or S-R isomers of zeaxanthin, and they do not synthesize significant quantities of other carotenoids which might compete against zeaxanthin for alimentary uptake after oral ingestion.
REFERENCES:
patent: 3841967 (1974-10-01), Dasek et al.
patent: 3891504 (1975-06-01), Schocher et al.
patent: 3951743 (1976-04-01), Shepherd et al.
patent: 4153615 (1979-05-01), Saucy
patent: 4522743 (1985-06-01), Horn et al.
patent: 4726955 (1988-02-01), Horn et al.
patent: 4851339 (1989-07-01), Hills
patent: 4952716 (1990-08-01), Lukac et al.
patent: 5180747 (1993-01-01), Matsuda et al.
patent: 5227507 (1993-07-01), Lukac et al.
patent: 5308759 (1994-05-01), Gierhart
patent: 5310764 (1994-05-01), Baranowitz et al.
patent: 5350773 (1994-09-01), Schweikert et al.
patent: 5356636 (1994-10-01), Schneider et al.
patent: 5382714 (1995-01-01), Khachik
patent: 5427783 (1995-06-01), Gierhart
patent: 5429939 (1995-07-01), Misawa et al.
patent: 5523494 (1996-06-01), Torres-Cardona et al.
patent: 5527533 (1996-06-01), Tso et al.
Bendich, A., et al, "Biological actions of carotenoids," FASEB Journal 3: 1927-1932 (1989).
Blumenkranz, M.S., et al, "Risk factors in age-related maculopathy complicated by choroidal neovascularization," Ophthalmology 93: 552-558 (1986).
Bone, R.A., et al, "Preliminary identification of the human macular pigment," Vision Res. 25: 1531-1535 (1985).
Bone, R.A., et al, "Stereochemistry of the macular carotenoids," Invest. Ophthalmol. Vis. Sci. 34: 2033-2040 (1993).
Bone, R.A., et al, "Distribution of macular pigment stereomers in individual eyes, including those with age-related macular degeneration," abstract, ARVO Abstracts Investig. Ophthalmol. Visual Science 35: 1502 (1994).
Christen, W.G., "Antioxidants and Eye Disease," Amer. J. Medicine 97 (suppl. 3A): 14S-17S (1994).
Columbo, V.E., et al, "Structures and properties of stabilized vitamin and carotenoid dry powders," Food Structure 10: 161-170 (1991).
di Mascio, P., et al, "Lycopene as the most efficient biological carotenoid singlet oxygen quencher," Archives of Biochemistry and Biophysics 274: 532-538 (1989).
di Mascio, P., et al, "Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols," Am. J. Clin. Nutr. 53: 194S-200S (1991).
Dorey, C.K., et al, "Lipofuscin in aged and AMD eyes," in Retinal Degeneration (Hollyfield et al, editors, Plenum Press, New York, 1993).
Eye Disease Case-Control Study Group, "Antioxidant status and neovascular age-related macular degeneration," Arch. Ophthalmol. 11: 104-109 (1993).
Eye Disease Case-Control Study Group, "Risk factors for neovascular age-related macular degeneration," Arch. Ophthalmol. 10: 1701-1708 (1992).
Gerster, H., "Review: antioxidant protection of the ageing macula," Age and Aging 20: 60-69 (1991).
Goldberg, J., et al, "Factors associated with age-related macular degeneration," Amer. J. Epidemiology 128: 700-710 (1988).
Haegerstrom-Portnoy, G., "Short-wavelength-sensitive-cone sensitivity loss with aging: a protective role for macular pigment?," J. Opt. Soc. Am. A5: 2140-2144 (1988).
Handelman, G.J. and Dratz, E.A., "The role of antioxidants in the retina and retinal pigment epithelium and the nature of prooxidant-induced damage," Adv. Free Radical Biology & Medicine 2: 1-23 and 55-57 (1986).
Handelman, G.J., et al, "Carotenoids in the human macula and whole retina," Invest. Ophthalmol. Vis. Sci. 29: 850-855 (1988).
Malinow, M.R., et al, "Diet-related macular anomalies in monkeys," Invest. Ophthalmol. Vis. Sci. 19: 857-863 (1980).
Mares-Perlman, J.A., et al, "Serum antioxidants and age-related macular degeneration in a population-based case-control study," Arch. Ophthalmol. 113: 1518-1523 (1995).
National Advisory Eye Council, Vision Research Research: A National Plan, 1994-1998 (NIH Publication 93-3186), pp. 55-64, 336, and 356 (1993).
Seddon, J.M., et al, "Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration," JAMA 272: 1413-1420 (1994).
Sperduto, R.D., et al, "Do we have a nutritional treatment for age-related cataract or macular degeneration?," Arch. Ophthalmol. 108: 1403-1405 (1990).
Taylor, A., et al, "Oxidation and aging: impact on vision," Journal of Toxicology and Industrial Health 9: 349-371 (1993).
West, S., et al, "Are antioxidants or supplements protective for age-related macular degeneration?" Arch. Ophthalmol. 112: 222-227 (1994).
Garnett Kevin M.
Gierhart Dennis L.
Guerra-Santos Luis H.
Applied Food Biotechnology, Inc.
Jarvis William R.A.
Kelly Patrick D.
LandOfFree
Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-55350